Irish biotech firm BioAtlantis to lead €1.7m EU research project on antibiotics

24 Jan 2013

Share on FacebookTweet about this on TwitterShare on LinkedInShare on Google+Pin on PinterestShare on RedditEmail this to someone

Share on FacebookTweet about this on TwitterShare on LinkedInShare on Google+Pin on PinterestShare on RedditEmail this to someone

Irish biotechnology company BioAtlantis is to lead a €1.7m research project that will aim to validate natural alternatives to the use of in-feed growth promoting antibiotics in the agricultural sector, a practice that was banned by the EU in 2006.

BioAtlantis will lead a consortium of EU firms and universities in the two-year Thrive-Rite project, with the aim of validating four natural alternatives to the use of in-feed growth promoting antibiotics. If the research proves successful it is hoped that this will reduce the incidence of diseases such as salmonella and E.coli.

The project has been awarded €1.7m under the EU’s Research Framework programme (FP7). lt will follow eight years of collaborative research between BioAtlantis and the Agriculture & Food Science Centre at University College Dublin.

The Tralee, Co Kerry-based BioAtlantis specialises in the research, development and manufacture of plant biostimulants and animal prebiotics. In 2010 the company received a €750,000 investment from the Bank of Ireland Kernel Capital Fund.

BioAtlantis employs 15 people and has a processing facility in Kanturk, Co Cork.

66

DAYS

4

HOURS

26

MINUTES

Buy your tickets now!

Carmel was a long-time reporter with Siliconrepublic.com

editorial@siliconrepublic.com